Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Cabazitaxel For Metastatic Gastroesophageal Adenocarcinomas That Have Relapsed After At Least One Line Of Chemotherapy

NCT01365130 is registered in ClinicalTrials.gov with howard safran as lead sponsor.

NCT NCT01365130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01365130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Cabazitaxel For Metastatic Gastroesophageal Adenocarcinomas That Have Relapsed After At Least One Line Of Chemotherapy
Lead sponsor
howard safran
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2011
Completion date
August 31, 2013
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal, gastric cancer, gastrooesophageal cancer